116 related articles for article (PubMed ID: 38387911)
21. [Effect of silencing NOTCH1 gene by shRNA interference on AKT/mTOR pathway in mantle cell lymphoma].
Huang YQ; Huang XL; Ma XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1616-20. PubMed ID: 25543484
[TBL] [Abstract][Full Text] [Related]
22. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
Zhao X; Bodo J; Sun D; Durkin L; Lin J; Smith MR; Hsi ED
Br J Haematol; 2015 Mar; 168(5):765-8. PubMed ID: 25284608
[No Abstract] [Full Text] [Related]
23. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
Mu J; Liu M; Wang J; Meng J; Zhang R; Jiang Y; Deng Q
Adv Clin Exp Med; 2022 Mar; 31(3):327-335. PubMed ID: 35148570
[TBL] [Abstract][Full Text] [Related]
25. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
26. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
[TBL] [Abstract][Full Text] [Related]
27. [Myrislignan Induces Apoptosis in Gastric Cancer Cell Line Through PI3K/AKT Signaling Pathway].
Zhou YJ; Pan YY; Yang LJ; Bie MJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 54(1):136-141. PubMed ID: 36647656
[TBL] [Abstract][Full Text] [Related]
28. [Anti-tumor effects of 13-cis-retinoic acid combined with interferon α-2b in animal model of mantle cell lymphoma].
Wen JJ; Liu ZB; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):784-789. PubMed ID: 27719722
[TBL] [Abstract][Full Text] [Related]
29. Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
Chen H; Sheng H; Zhao Y; Zhu G
Med Sci Monit; 2020 Dec; 26():e928403. PubMed ID: 33382670
[TBL] [Abstract][Full Text] [Related]
30. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
[TBL] [Abstract][Full Text] [Related]
31. [PLK1 Expression in Mantle Cell Lymphoma and Its Clinical Significance].
Shen LY; Lin CM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):833-838. PubMed ID: 31204940
[TBL] [Abstract][Full Text] [Related]
32. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
33. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
34. [Antiproliferative effects of LY294002 on MCL Jeko-1 cell line and its mechanism].
Chen HP; Huang YQ; Ma XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1183-6. PubMed ID: 24156430
[TBL] [Abstract][Full Text] [Related]
35. [Mitochondrial coenzyme Q attenuates lipopolysaccharide-induced mitochondria-dependent apoptosis in type II alveolar epithelial cells via phosphatidylinositol 3-kinase/Akt pathway].
Zhou J; Gao J; Fang Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):378-382. PubMed ID: 35692202
[TBL] [Abstract][Full Text] [Related]
36. [Antiproliferative effect of silencing mTOR gene on MCL Jeko-1 cell line and its mechanism].
Zheng R; Huang Y; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Jan; 36(1):49-52. PubMed ID: 25641147
[TBL] [Abstract][Full Text] [Related]
37. [Effect of Chlorambucil on the Apoptotic Signaling Pathway in Lymphoma Cells].
Guo JX; Zhou YH; Pan JX; Guo XZ; Huang YQ; Guo YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1360-1365. PubMed ID: 30295251
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
[TBL] [Abstract][Full Text] [Related]
39. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
40. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
